Skip to main content
Clinical Trials/NCT06049355
NCT06049355
Recruiting
Phase 2

EMBark on RAdiation Therapy With a Clinic-based Exercise Program: EXERCISING TOGETHER

OHSU Knight Cancer Institute1 site in 1 country400 target enrollmentApril 18, 2024

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Breast Carcinoma
Sponsor
OHSU Knight Cancer Institute
Enrollment
400
Locations
1
Primary Endpoint
Physical functioning
Status
Recruiting
Last Updated
11 months ago

Overview

Brief Summary

This phase II trial tests how well an exercise intervention, Exercising Together, works in preventing declines in physical and mental health in couples during radiation treatment for cancer. Treatments for cancer can cause side effects such as fatigue as well as strain on relationships. Exercising Together is a partnered exercise program that adds communication, collaboration and support between partners during exercise to fortify the relationship and amplify the benefits of physical training. Exercising Together program may be effective on the mental and physical health of couples during radiation treatment for cancer.

Detailed Description

PRIMARY OBJECTIVE: I. To test the effectiveness and mechanisms of the adapted Exercise Together intervention on mental and physical health of couples (Aims 1 \& 2). SECONDARY OBJECTIVE: I. To gain better understanding of the implementation context and implementation outcomes (Aim 3). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients and partners undergo Exercising Together exercise program during radiation therapy on study. Patients also undergo collection of blood samples throughout the trial. ARM II: Patients and partners receive educational materials specific to exercise. Patients also undergo collection of blood samples throughout the trial.

Registry
clinicaltrials.gov
Start Date
April 18, 2024
End Date
September 1, 2028
Last Updated
11 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kerri Winters

Principal Investigator

OHSU Knight Cancer Institute

Eligibility Criteria

Inclusion Criteria

  • INTERVENTION (SURVIVORS) INCLUSION
  • Histologically confirmed prostate cancer or breast cancer without evidence of metastatic disease
  • Confirmed by review of the electronic medical record (EMR) and subsequently recorded in Survivor Health History. In cases where the EMR isn't clear, their Oregon Health \& Science University (OHSU) provider will be contacted for confirmation. For non-OHSU patients, we'll initially collect their cancer health history by a self-report questionnaire and confirm when we receive the survivor's outside medical record (through a signed Release of Information)
  • Scheduled to receive radiation therapy for curative intent
  • Confirmed by review of the EMR and subsequently recorded in Survivor Health History. In cases where the EMR isn't clear, their OHSU provider will be contacted for confirmation/ For non-OHSU patients, we'll initially collect their cancer health history by a self-report questionnaire and confirm when we receive the survivor's outside medical record (through a signed Release of Information)
  • Co-residing with an intimate partner or spouse who is willing to participate
  • Confirmed by self-report on the Demographic Questionnaire
  • INTERVENTION (SURVIVORS AND PARTNERS) INCLUSION
  • 18 years of age and older
  • For survivors: confirmed by review of the date of birth as documented in the Electronic Medical Record (EMR) and subsequently recorded in Survivor Health History. For non-OHSU patients, we'll collect their age by self-report on the Survivor Health History

Exclusion Criteria

  • INTERVENTION (SURVIVORS AND PARTNERS) EXCLUSION
  • Cognitive difficulties that preclude answering the survey questions, participating in the exercise classes or performance tests, or providing informed consent
  • In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigator, Kerri Winters-Stone
  • A medical condition, movement or neurological disorder, or medication use that contraindicates participation in moderate intensity exercise. Specific contraindications include the following: poorly controlled diabetes, recent cardiac event, neuromuscular disease, untreated orthostatic hypertension, recent surgery, acute hernia, acute rheumatoid arthritis, severe memory disorders, severe balance disorder, inability to ambulate without a walker or wheelchair, inability to stand for 3 minutes, severe hearing or vision problem
  • Confirmed by a combination of reviewing the EMR, self-report on the Health History Questionnaire, Charlson Comorbidity Index questionnaire, and/or by physician clearance. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible. For Spouse/Partner: must answer \'No\' to American College of Sports Medicine pre-participation screening questions. If spouse/partner answers \'Yes\' to either question they may be required to obtain physician clearance prior to becoming eligible. Physician clearance may also be requested at the discretion of the principal investigator.

Outcomes

Primary Outcomes

Physical functioning

Time Frame: Baseline, Months 2, Month 4, and Month 6

Measured by the Physical Performance Battery (PPB) to determine a person's ability to perform daily tasks independently. The PPB consists of 3 timed tests: 5 repeated chair stands, standing balance, and usual pace gait speed over 4 meters. Each test is scored 0 (unable) to 4 (completes without difficulty), based on quartiles of performance, then scores are summed. The possible range of scores is 0-12.

Anxiety

Time Frame: Baseline, Month 1, Month 2, Month 4, and Month 6

Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) anxiety short form using questions on a scale ranging from 1 (never) to 5 (always).

Secondary Outcomes

  • Sleep Behavior: total sleep time(Baseline, Months 2, Month 4, and Month 6)
  • Sexual function and satisfaction(Baseline, Month 1, Month 2, Month 4, and Month 6)
  • Changes in patient-reported symptoms(Baseline, Month 1, Month 2, Month 4, and Month 6)
  • Inflammation - high sensitivity C-Reactive Protein (hsCRP)(Baseline, Months 2, and Month 6)

Study Sites (1)

Loading locations...

Similar Trials